Top Tweets for #kRAS
Stumbled across this store when I was in Dubrovnik and had to stop for a photo. For a second I thought I’d found the global headquarters of #KRAS inhibitors! 😄 🧬
Between all the excitement in #oncology and this iconic Croatian chocolate brand, “KRAS” is definitely having a moment.
#KRASinhibitors #Oncology #CancerResearch
For all those interested in staying connected to our new information hub, you can find our first official #newsletter below, alla bout #autoinflammatory updates from #EULAR2026!!
#VEXAS #histiocytosis #KRAS
⬇️⬇️
🔗https://t.co/ED7Dtn7L4n
👌Promising Phase 3 results for divarasib. @Roche
🚨If the full data confirm improvements in survival with a manageable safety profile, this could mark an important step forward for patients with previously treated #KRAS G12C-mutated #NSCLC.
Roche's divarasib just beat both Amgen's Lumakras AND BMS's Krazati head-to-head in Phase 3 KRAS G12C lung cancer.
Impressive. But analysts are right to pump the brakes. The second-line market is worth ~1-2B CHF. The real game is Krascendo-2, the first-line combo with Keytruda, where the prize jumps to ~5B CHF.
Win the second line, sure. But you haven't won the war until you crack first-line. $RHHBY
https://t.co/mtNezZx63a
Promising data coming with #kras inhibitions in solid tumors isolated or in combinations
Stay @OncoAlert @KRASKickers
#lungcancer #lcsm
@Roche says divarasib showed superiority in a Phase III non-small cell lung cancer trial, sharpening the competitive picture in KRAS G12C-mutated NSCLC.
https://t.co/39PwIhiLft
#NSCLC #LungCancer #KRAS
🌟 #ASCOMOS26 #AGA postive #LCSM
🔥Beyond our Common Foes in Lung Cancer
✅Rare Drivers in NSCLC: What Oncologists Must Know
🎙️ @mollylisc
🎯 #ALK Lorlatinib, Neladalkib
🎯 #RET adjuvant Selpercatinib
🎯 #KRAS Divarasib, Olomorasib, Calderasib, Daraxonrasib
🔗 https://t.co/nHNial2FSw
@OncoAlert @Larvol @ALKPositiveinc @RetRenegades @KRASKickers
🧬📊 Positive Phase 3 KRAS Results
@Roche 's divarasib outperforms approved KRAS therapies in Phase 3.
👉 https://t.co/O5CzzdAJJ5
#Oncology #KRAS #ClinicalTrials #Biopharma
POV: Your Apple Watch thinks something is wrong…
…but you’re just about to present at #ESMOGI26. 😄⌚️💕💗💜
Discussing the Phase II GLEAM study and joining conversations on the future of pancreatic cancer.
Worth every heartbeat. 💗
#PancreaticCancer #GIOncology #KRAS #ClinicalTrials @myESMO @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @oncodaily @OncoDailyGI
🚨 #KRAS alert!
Out in @CD_AACR our collaborative effort lead by @AmbrogioLab where we demonstrate that acquired #EML4ALK rearrangements drive resistance to KRAS G12C (OFF) inhibitors by restoring RAS signaling through wild-type KRAS, highlighting a therapeutically actionable bypass mechanism.
@OncoAlert @KRASKickers @AACR @IASLC @DanaFarberNews
@ElizSMcKenna @DanaFarber @unito @EdoardoGarbo @DrMarkAwad
https://t.co/sePituhuoW
🚨Press release data 👉Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer #KRAS @OncoAlert @oncodaily #PrecisionMedicine https://t.co/wpgWXD2q60
A few years ago we asked whether KRAS could be drugged. Today we are discussing the best sequence of KRAS inhibitors, chemotherapy and combinations. Exciting times ahead, with many challenges still to solve. #ESMOGI26 #PancreaticCancer #KRAS
📣 Divarasib beats sotorasib/adagrasib head-to-head in 2L #KRAS G12C #NSCLC (Krascendo 1) - @genentech press release
✅ significant PFS + OS benefit.
🔍 First 2nd-gen vs 1st-gen head-to-head, numbers pending congress.
https://t.co/enh0boYQx9
@Roche Reports P-III (Krascendo 1) Trial Results on Divarasib for KRAS G12C-Mutant NSCLC
#roche #piii #krascendo1 #clinicaltrial #divarasib #nsclc #krascendo2 #krascendo3 #oncology #lungcancer #kras
https://t.co/I5gXT6u6ja
What are the clinical implications of emerging KRAS research for oncology APs?
Find out at the upcoming RQI Forum webinar featuring Erin Pierce, MSN, APRN, FNP-C.
📅 July 14 | 6 PM ET
https://t.co/uQ6coZORi2
#KRAS #Oncology #ClinicalTrials
🧬 Biomarker Spotlight: KRAS G12C
Once considered "undruggable," KRAS G12C is now a targetable biomarker with FDA-approved therapies for advanced NSCLC.
Precision medicine starts with precision testing.
#KRAS #LungCancer #NGS #PrecisionOncology #4baseCare #OncoBuddy
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.7M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.6M followers
Lady Gaga
@ladygaga
73.1M followers
Virat Kohli
@imvkohli
70M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.8M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers